Showing posts with label Market Outlook. Show all posts
Showing posts with label Market Outlook. Show all posts

Monday, February 25, 2019

Landscape Of The Europe Ophthalmology Devices Market Outlook: Ken Research

Europe Ophthalmology Devices Market
Ophthalmology is the subdivision of medicine that pacts with the anatomy, physiology, and diseases of the eye. Ophthalmology device manufactures, medical companies, distributors, healthcare institutions and research and development firms are recently taking efforts to establish new medical devices to attain competitive advantage. Ophthalmology devices are generally utilized for treating various eye conditions and infections. As such devices help in reducing the duration of treatment and suggest quality eye care to patients, they support in introducing the eye-treatment procedure more convenient for the patients and ophthalmologists. In addition, the players of this market are doing effective efforts for increasing the efficiency of the devices and demand of such devices whereas, with the continuous developments in these devices lead the market grew more significantly and enable the players for attaining the highest market share in Europe during the forecasted period.
According to the report analysis, ‘Europe Ophthalmology Devices Market Research Report’ states that there are several key players which are presently functioning in this market more actively for registering the highest market growth and attaining the effective value of market share while doing effective developments in the technology and techniques of doing work which further become beneficial for earning high amount of profit more significantly include Essilor, Marco, Heidelberg Engineering GmbH., HAAG-STREIT GROUP, Johnson & Johnson Surgical Vision, Inc., HOYA Corporation, CIBA VISION, NIDEK CO.LTD., TOPCON CORPORATION, ZEISS International, Canon Inc., CooperVision, Bausch & Lomb Incorporated, STAAR SURGICAL, AcuFocus, Inc., Ziemer Ophthalmic Systems and several others. Moreover, many of the players of this market are aiming in establishing new and innovated technologies in the respective business premises for producing the high amount of revenue and leading the fastest market growth during the forecasted period more efficiently.
Europe ophthalmology devices market is expected to register a healthy CAGR of 3.9% in the forecast period of 2019 to 2026. Whereas, the market of ophthalmology devices in Europe is segmented differently which majorly includes product type, application, end-user, and geography? Moreover, on the basis of application, the market is further segmented into Vision Care, Ophthalmic Wound care, Cataract Surgery, Oculoplastics and several other meanwhile, the sector of end-user is divided into Hospitals, Diagnosis Clinics, Franchise Optical Stores, Eye Research Institutes, Government Agencies, and Academics. Not only has this, with the effective applications and various end-users the market of Ophthalmology is spread across Europe more efficiently such as Germany, U.K., France, Spain, Italy, Switzerland, Netherlands, Turkey, Belgium, Russia and Rest of Europe.
With all this, the market is having few restraints which hinder the market growth such as high cost of the equipment and surgery and poor indemnification process for the ophthalmic surgery. However, the significant increase in the number of contact lens users, developments in the technology and rising prevalence of eye diseases are some effective market growth drivers. Nevertheless, the market is having few growth opportunities such as programs and initiatives to decrease the burden of eye diseases and less acceptance of the phacoemulsification and premium IOLS in underdeveloped countries. Therefore, in the forecasted period, it is anticipated that the market of ophthalmology devices will increase in the Europe region more significantly over the near future.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , ,
Location: Europe

Friday, January 11, 2019

Increasing Immunization Rates and Immunization Endorsements to Drive Conjugate Vaccine Market in North American Region: Ken Research

North America Conjugate Vaccine
Conjugate vaccines cure contagious diseases. It consists of polysaccharide coatings on microorganisms and germs which help to cure the disease. These vaccines link the polysaccharide coatings to a bacterium by producing response& immunity. Some examples of these vaccines are a pneumococcal vaccine, meningococcal vaccine, and Haemophilus influenza type B (Hib) vaccine etc. Meningococcal vaccines are used to prevent meningitis.
The key advantages of conjugate vaccines are longer fixed protection, the formation of herd insusceptibility, better immune & memory response and safety of children& toddlers. Additionally, some of the side-effects are muscle pain, vomiting, low fever, redness, tired feeling, diarrhea, swelling, headache, irritability, obsessiveness, loss of hungriness and sleepiness and many others.
According to study, “North America Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently operating in the North America conjugate vaccine market are Merck & Co. Inc., GlaxoSmithKline, Bavarian Nordic, Sanofi Pasteur SA, Pfizer Inc., SutroVax Inc., CSL Limited, Novartis AG, Nuron Biotech Inc. These key players competing with each other and offer many products with many different brands.
The conjugate vaccine is classified mainly in two type multivalent conjugate vaccines and monovalent conjugate vaccine. Based on the pathogen type, this market is segmented into viral conjugate vaccine market, bacterial conjugate vaccine and combination (bacterial & viral) conjugate vaccine. Based on the disease indication, the market is segmented into meningococcal, pneumococcal, Haemophilus influenza type B (Hib) and diphtheria tetanus pertussis (DTP) etc. In addition, based on the end-user, the market is segmented into adult and pediatric.
The North American conjugate vaccine is largely driven by an increase in diagnosis and treatments. Some of the other growth factors are increasing immunization rates & immunization endorsements, rising in a number of regulatory approvals, growing determinations for the implementation of suitable preventive broadcast methods, improvement in patient compliance, growing commonness of diseases affected by germs (Neisseria meningitides and Streptococcus pneumonia), increasing technological advancements etc.
North America is a soaked market for these vaccines. The growth of the market is registering key challenges of complex production procedure, emerging manufacturers, the situation of oligopoly, uncertainty about the future of government initiatives and low convenience to vaccines in distant areas. In addition, the demand for adult vaccines has reduced due to the decreasing aging population in the region.
The recommended dosages & vaccines are reorganized on a regular basis to fulfill with dominant infectious mediators. The Centers for Disease Control and Prevention (CDC) is a government agency in the U.S, which has its private immunization plan for US inhabitants. It helps in increasing the efficiency of managed vaccines, which thus raises the demand for the manufactured goods, primary to increase in market trades.
It is estimated that the conjugate vaccine market in North America is expected to reach US$ 16.2 billion, at a CAGR of 3.2%, by 2023. In terms of volume, it is expected that the market to reach 286.6 million units, expanding at a CAGR of 3%. It is predicted that the future of the market to be bright due to extensive routine immunization programs in developing economies.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , ,
Location: North America

Thursday, January 10, 2019

Modernization of Healthcare Infrastructure, Followed by Growing Disposable Income to Support Conjugate Vaccine Market in European Region: Ken Research

Europe Conjugate Vaccine Market
Conjugate vaccines are manufactured by linking an antigen to a protein molecule. It comprises of a polysaccharide antigen joined a carrier protein. The grouping of an antigen with protein forms a substance which is identifiable to the blood cells in the humanoid blood, resulting in a robust immune response. It is used for immunizing children against microorganism that has polysaccharide capsular. Conjugate vaccines provide enduring immunity. Some of the major examples of the products are shingles, Hib (Haemophilus influenza type b) disease, hepatitis B, Pneumococcal Conjugate Vaccine (PCV) and whooping cough.
In U.K., the main brand of PCV is called prevenar 13 which is recommended for all age’s people with some health restrictions who are at greater risk of obstacles such as diabetes, chronic lung conditions, cerebrospinal fluid leaks, chronic liver disease (heart disease & kidney disease), immunosuppression and cochlear implants etc.
According to study, “Europe Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently working in the Europe conjugate vaccine market are Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Novartis AG, Pfizer Inc., CSL Limited.
The use of conjugate vaccine can be used for influenza, hepatitis, HPV (human papillomavirus), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, herpes zoster, and other disease indications. Moreover, based on the route of administration, the market is segmented into oral administration, subcutaneous administration and intramuscular administration and many others.
Some of the major benefits of conjugate vaccinations are the cost-effectiveness; elicit long term protections, high efficacy against vaccines and high serotype coverage etc. Some of the disadvantages are complex & complicated preparation loss of immunogenicity etc. Moreover, these vaccinations may cause side effects such as tenderness, loss of appetite, redness, allergic reaction, slight fever and swelling at the site of the shot.
The European Centre for Disease Prevention and Control (ECDC) is a government agency formed with an objective to support infective diseases. Agency also assists by providing toolkits and immunization program for managers & public health specialists to efforts in addressing vaccine consumption awareness. In addition, the National Infant Immunization Program (NIIP) is a government synchronized authority, which is mainly help in preventing vaccine avoidable diseases in children.
The market of Europe conjugate vaccine is mainly driven by increasing prominence on &availability of resources for research and development (R&D), followed by raising awareness about the convenience of a higher number of vaccines, modernization of healthcare infrastructure, growing disposable income, rising prevalence of infectious disease, increasing aging population and increasing advancements in medical science, increasing government vaccination programs & initiatives etc. Apart from the significant efforts market also face some of the major challenges which include product recalls, the high cost of conjugate vaccines development and inadequate access to vaccines etc. In Europe some of the new opportunities expected to focus on therapeutic vaccines, high growth prospects in the emergent market and the use of an adjuvant in vaccines etc.
It is expected that the European conjugate vaccine market to reach US$ 8.9 billion, at a CAGR of 3.6%, by 2023. By volume term, it is estimated that this market will be reached 504.4 million units, growing at a CAGR of 3.7%. In the near future, it is predicted that the market to grow progressively owing to the rising implementation of cancer medicinal vaccines.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , ,
Location: Europe

Wednesday, January 9, 2019

Increasing Geriatric Population, Followed By Growing Awareness to Drive the Conjugate Vaccine Market in the Asia-Pacific Region: Ken Research

Asia-Pacific Conjugate Vaccine Market
The conjugate vaccine comprises microbial capsular polysaccharide with a protein to boost immunogenicity and protect beside invasive diseases. It is also known as the immunogen conjugate vaccines. It combines a pathetic antigen with a robust antigen by which the protected system has a stronger response to the pathetic antigen. It includes linking external coats (polysaccharide) to proteins (toxins). It reduces the vaccine serotypes in the nasopharynx and reduces the local pneumococci extent which can cause Acute Otitis Media (AOM) or sinusitis to nearby mucosa. Some of the essential features are longer lasting protection, the creation of herd immunity improved immune & memory response and protection of infants & toddlers etc. All these vaccines are approved by the Food & Drug Administration (FDA).
Some of the major side-effects associated with the conjugate vaccine are joint pain or muscle pain, low fever, vomiting, redness, swelling, headache, tired feeling, diarrhea, irritability, fussiness, loss of appetite and drowsiness.
According to study, “Asia-Pacific Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently working in the Asia-Pacific conjugate vaccine market are GlaxoSmithKline Plc., Fablife, Merck & Co. Inc., Green Signal Bio Pharma Limited, MedImmune LLC, Biological E. Limited, Johnson and Johnson, Sanofi Pasteur,Emergent BioSolutions Inc., Bharat Biotech, Pfizer Inc., Taj Pharmaceuticals Limited, CSL Limited, Novartis AG, Serum Institute of India. These key players are accomplishment moderately for removing the limitations by adopting the operative strategies & policies.
On the basis of disease indication, the Asia-Pacific conjugate vaccine market is segmented into pneumococcal, diphtheria tetanus pertussis (DTP), hemophilia influenza type B (Hib), meningococcal and others. Pneumococcus and Hibcause diseases containing infections such as pneumonia and meningitis. On the basis of the end-user, the market is segmented into adult and pediatric.
India is projected to designate the emergent market owing to the government’s focus on research and development (R&D) in the life sciences province. The Universal immunization program (UIP) offers Pneumococcal Conjugate Vaccine (PCV) to those who need most such as underserved and underprivileged people. Additionally, the major cause of bacterial meningitis is Hib. Hib is as a liquid pentavalent vaccine (LPV) collective with HepB in 10-dose and DPT. Moreover, the Ministry of Health and Family Welfare (MoHFW) and Government of India (GoI) lead the conjugate vaccines in several states.
In Japan, the National Immunization Program launched two vaccines: PCV–13 and PPSV–23 for the elderly (65 & above). These vaccines are available for the inhibition of Streptococcus pneumonia-related diseases.
The market of conjugate vaccine market is mainly driven by increasing geriatric population, followed by growing awareness about the convenience of a higher number of vaccines, growing disposable income, modernization of healthcare infrastructure, rising healthcare expenditure and growing medical tourism industry. Apart from advantages, some of the key challenges are accessibility & availability of conjugate vaccines in distant areas and high prevalence of chronic diseases etc.
It is expected that the conjugate vaccines market in Asia-Pacific to reach US$ 66.6 billion, at a CAGR of 23.5%, by 2023. In terms of volume, it is estimated to reach 6,883.5 million units, expanding at a CAGR of 21.8%. In the upcoming years, it is projected that the market to grow due to effective investment by the new entrants.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , ,
Location: Asia

Tuesday, January 8, 2019

The Developing Health Care Facilities to Simplify the Conjugate Vaccine Market in Latin American Region Over the Forecast Period: Ken Research

Latin America Conjugate Vaccine
Conjugate vaccines are used in preventing the diseases by invoking an immune response to an antigen, the external part of a bacteria or virus that the immune system recognizes. The treatment is usually accomplished with an attenuated or dead version of a pathogenic bacterium or virus in the vaccine so that the immune system can detect the antigen later in life. The Conjugate vaccines are used for treating Hepatitis B, Hib (Haemophilus influenza type b) disease, diphtheria tetanus pertussis (DTP), Meningococcal disease, HPV (Human papillomavirus), Pneumococcal disease, Whooping cough, and Shingles. These vaccines have innovative arrangements of adding the immune system which is used broadly to produce protection besides conquering pathogens or to create specific antibodies against a goal molecule.
Conjugate vaccines are defined by two type monovalent conjugate vaccines and multivalent conjugate vaccines. Monovalent vaccines aimed to vaccinate against a single microorganism or single antigen while multivalent conjugate vaccines vaccinate against two or more draining of the same viruses.
According to study, “Latin America Conjugate Vaccine Market (2018-2023)” some of the major companies that are currently working in the Latin America conjugate vaccine market are Pfizer Inc., Sanofi Pasteur, Merck & Co., CSL Limited, Novartis. All these vendors launching new products in the market owing to rising research & development (R&D) spending and violent strategies.
Based on the application, the conjugate vaccine is segmented into the academic institute, research institute, pharmaceuticals industries, and others. The major benefits are the ability to elicit immunological memory, reduce asymptomatic carriage of the bacteria, longer fixed protection, the establishment of herd insusceptibility, more durable immunity, low cost, easy transportation. In addition, some of the major disadvantages include no local immunity, obsessiveness, and loss of hungriness etc.
The Brazilian National Immunization Program (NIP) is a government authority, which is responsible for arranging distinct sector vaccination activities formerly organized in remote programs of infection control. NIP offers several conjugate vaccines such as Pneumococcal 10-valent conjugate vaccine (PCV10), Hib and other vaccines.
The Latin America vaccine market is generally driven by increasing chronic diseases, growing exertions for the acceptance of suitable preventive broadcast methods, enhancement in patient acquiescence along with an accumulative product pipeline, longer immunity and need of better safety of vaccines, widespread routine vaccination programs, rising adoption of cancer therapeutic vaccines, control strategies and government initiatives. In addition, some of the major drawbacks are low accessibility, complex manufacturing procedure, limited awareness of Hib disease, malpractices by top vaccine manufacturers, recent incidents of frauds, slow introduction in low-income countries, low penetration rate, emerging companies, the situation of oligopoly, pricing inefficiencies and the complicated manufacturing processes and others. Additionally, some of the new opportunities associated with the conjugate vaccine market are raising investment in developing countries.
It is estimated that the conjugate vaccine market in Latin America to reach at USD 5.4 billion, at a CAGR of 20.4 %, by 2023. In terms of volume, it is expected that market to reach by 839.2million units, expanding at a CAGR of 20.1%. In the coming years, it is predicted that the market grows progressively due to rising technological advancements.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , ,
Location: Latin America

Monday, January 7, 2019

Drawing A Comparative Study Between Smartphone And PLC Markets In Asia – Pacific Region: Ken Research

Asia-Pacific PLC Market
A Programmable Logic Controller (PLC) is a form of regarded computer used in industries for automation. They are programmed to automatize specific processes, machine functions and sometimes the entire production line. PLCs pick up information and data from connected input devices and process these data and trigger output upon their programmed instructions. Based on incoming inputs and outputs, real-time insights into machine productivity, the temperature can be measured and the processes can be automated. They are formable and are controlled by robots, which are easily adaptable.
According to study Asia–Pacific Programmable Logic Controllers (PLC) Market by Architecture, Product, Industry Vertical and Country 2014-2025: Segment Analysis, Trend Forecast, and Business Strategy gives a detailed analysis and data for annual revenue which is available for 2014-2025. The disruption of key national markets by product type and industry vertical over the forecast years are also included. The report consists of a competitor’s analysis and the predicted manufacture trend; and profiles PLC vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia – Pacific PLC market and industry is assayed quantitatively and qualitatively through GMD's Risk Assessment System. The major players in the market are ABB Ltd., B&R Industrial Automation GmbH, Emerson Electric Co., General Electric Co., Hitachi, Ltd., Honeywell International Inc., IDEC Corporation, Mitsubishi Electric Corp., Omron Corporation, Robert Bosch GmbH, Rockwell Automation Inc., Schneider Electric SE, Siemens AG, and Yokogawa Electric Corporation.
 Asian-Pacific market over the last few years has seen a surge in specialization and advancements in digital technologies. This has enabled users to benefit from low – cost and efficient PLC software without dependence on licensing – the based product of traditional PLC vendors. Modern-day PLC hardware is made up of microcontrollers which give users the power to build and execute super – fast controller applications for any type of industries. Thus, PLCs are evolving and adopting Smartphone models where devices have applications that enable users to execute a particular task. Companies like Bosch Rexroth AS launched a version of PLC which works under an open source operating software that can be connected with open source coder’s repository. Thus, this enables users to use free software or build their own applications based on their requirement.
The PLC market is undergoing a type of disruption the Smartphone faced during 2007 with the advent of app stores. The traditional PLC players will see a reduction in revenues if they fail to adapt to the changing dynamics in the market and customize according to the customer demands.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , , ,
Location: Asia

Wednesday, December 19, 2018

Profitable Landscape Of The Conjugate Vaccine In India Market Outlook: Ken Research

India Conjugate Vaccine Market
India is projected to be the fastest rising market for the conjugate vaccines in the near future. Meanwhile, the conjugate vaccine is a category of vaccine that encompasses bacterial capsular polysaccharide, connected to a protein to develop immunogenicity and safeguard against invasive diseases. India is one of the most prominent markets of conjugate vaccines. Moreover, India is predicted to be the fastest rising market because of the government’s focus on research and development in the life sciences domain. By making Pneumococcal Conjugate Vaccine (PCV) obtainable under the Universal immunization program (UIP), the government of India is guaranteeing reasonable access to those who need them the most-the disadvantaged and underserved. Hib is one of the principal cause of bacterial meningitis in India and a foremost cause of childhood pneumonia. The creation of LPV in India is a noteworthy milestone and a step forward towards quickening child survival in the region, and progress towards accomplishing national health goals and the Millennium Development Goal 4. In addition, the key players of this market in India are playing an important role by spreading awareness which proved to be beneficial for acquiring the huge market share and leading the fastest growth in the near future.
According to the report analysis, ‘India Conjugate Vaccine Market (2018-2023)’ states that some of the major key players which are recently functioning in this market more dominantly for attaining the highest market share by doing more innovation and developments include GlaxoSmithKline, Pfizer Inc., Merck & Co., Novartis, Sanofi Pasteur, CSL Limited,  Bharat Biotech, Biological E. Limited, Serum Institute of India and several others. In India, the market of conjugate vaccine is segmented on the disease indication which includes Haemophilus influenza type B, pneumococcal, diphtheria-tetanus-pertussis, meningococcal and several others. Whereas, based on the end user, the market is split into adult and pediatric. Furthermore, many of the focused key players are investing in the research and development programs which benefitted for leading the fastest growth in India in the forecasted period.
India is projected to be the fastest growing market for the conjugate vaccines in the near future. Speedily growing population, growth in consumer awareness, rising disposable income and increased expenditure on healthcare, modernization of healthcare infrastructure and a rising medical tourism market will operate the Indian market growth. Moreover, the conjugate vaccine market in India is predicted to have significant extensive growth. Overdue overview of conjugate vaccines is likely to hold back the conjugate vaccine market. Though the commonness of chronic diseases is high, limited convenience and availability of conjugate vaccines in inaccessible areas can become a cause for concern. Complicated manufacturing can also be a major restraint for this market. Whereas, many of the key players are performing gently for removing the restraints by adopting the effective strategies and policies. Therefore, in the coming years, it is expected that the market of conjugate vaccine in India will increase more actively over the recent few years with the effective investment by the new entrants.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , , ,
Location: India

Monday, December 17, 2018

Use of Internet Increasing Mobile Financial Services: Ken Research

Mobile Financial Services Market in Asia-Pacific
A mobile financial service is an approach to offering financial services that combines banking with mobile wireless networks which enable users to execute banking transactions. Financial services encompass a broad range of businesses that manage money, including credit unions, banks, credit card companies, insurance companies, accountancy companies, consumer-finance companies, stock brokerages, investment funds, individual managers and some government-sponsored enterprises.
Mobile financial services can be broadly categorized into three areas: mobile payments, mobile banking, and microfinance. Mobile payments are online international payments for virtual goods: it is used to money paid for a product or service through a portable electronic device such as a tablet or cell phone, also known as m-commerce. Mobile banking includes financial transactions on a mobile device: it includes account information, transaction, investments and content services etc. Microfinance is a type of banking service that is provided to unemployed or low-income individuals or groups who otherwise would have no other access to financial services (loan & EMI payments).
According to study, “Mobile Financial Services in Asia-Pacific: Telco Service Portfolios and Positioning Strategies” some of the major companies that are currently working in the mobile financial services in Asia-Pacific are NTT Docomo, Telkmosel, Globe, Singtel, Google, Alipay, ANZ, Shinhan Bank, Samsung, Apple, Fuse, Axiata, Smart, Robi, BIMA ,Telenor, Ooredoo, Digicel, AIS, True, XL, Grameenphone, Rabbit Line Pay, Tameer Bank, Mynt, Ant Financial, Ayala Corp., MasterCard, PayPal, Alibaba, Bank of Philippines Islands, BancNet, CIMB.
Some mobile financial services technologies are short message service (SMS), mobile-enabled websites & browsers, mobile applications, and wireless payment technologies. SMS is a text messaging service component of phone, Web, or mobile communication systems: it uses standardized communications protocols to allow devices to exchange short text messages. The mobile-enabled Web site is designed to detect the type of device the customer is using (e.g., mobile device or desktop computer) and displays web pages in the best format for that device. Mobile financial applications are developed by or for financial institutions to allow customers to perform account inquiries, retrieve information, or initiate financial transactions. Wireless payment technology includes near field communication, image-based, carrier-based and mobile person to person.
Some applications of mobile financial service are SMS payments, chip payments, WAP banking, browser banking, remittances, person to person payments, merchant payments, account balances and alerts etc.
Bangladesh has a rapidly growing mobile financial services industry, with at least 17 providers already offering services on the market. By the end of 2016, the number of total agents was 7,10,026, the number of registered customers was almost 41.1 million, a number of total transactions were 1,473.2million and the number of total transactions was BDT 2346.9 billion. In the country, some guidelines services for mobile financial services are cash in/out using the mobile account, business to person payments, government to person payments, person to person payments, disbursement of inward foreign remittances etc.
In 2017, some trends are shaped into the mobile financial sector in India. These trends are Paytm thrives on demonetization, artificial intelligence powered chatbots, Unified payments interface growth, biometric authentication, and ATMs shut down. Additionally, regulators approved a new type of bank, known as payments banks, which can operate savings accounts accepting deposits of up to INR100,000 (roughly $1,500) and let customers make digital payments with their accounts.
In Asia-Pacific, mobile digital wallets are the most popular type of mobile financial service solution, enabling transactions from connected devices and a variety of providers to offer branded m-wallet services. There are some payment services are included such as Alipay, Tenpay, Payease, Asiapay, NTT Com Asia, PaySec, Red dot payment, Molpay, 2C2P, and context Asia etc.
In 2018, the central bank of Bangladesh allowed mobile operators to hold a maximum of 49 percent shares in MFS providers. Smartphone penetration of population is expected to reach 64% in Asia-Pacific, proving that more people have access to a mobile device than to banking services in the region. It is expected that mobile financial service market will reach US$72 billion by 2020.
To know more, click on the link below:-
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Posted by at No comments:
Labels: , , ,
Location: Asia
Subscribe to: Posts (Atom)